MODERN TREATMENT OF BACTERIAL VAGINOSIS IN THE SECOND TRIMESTER OF PREGNANCY
Bacterial vaginosis (BV) is a qualitative and quantitative disorder of the microflora of the urogenital tract. In BV, there is an absence or decrease in the total number of lactobacilli and an increase in the number of anaerobic microorganisms, such as Gardrenella vaginalis, Prevotella, Atopobium vaginae, Mobiluncus, Bifidobacterium, Sneathia, Leptotrichia, and other BV-associated bacteria [1]. BV is common in patients of reproductive age. The prevalence of BV in pregnant women is 8-51% [2]. BV in pregnant women is caused by complications during pregnancy, in particular chorioamnionitis, spontaneous miscarriage, premature rupture of the membranes, premature birth (PR) and a deficiency in the child's body weight at birth. Globally, the rate of neonatal mortality associated with HIV reaches 2.9 million. Over 80% of neonatal mortality is accounted for by newborns with OD, 2/3 of whom are premature, 1/3 are full–term infants with low body weight [3]. In the study by X. Zhang et al. Of the 186 pregnant women with gestational diabetes mellitus (GDM), 106 had an abnormal composition of the vaginal microflora. Patients with abnormal microflora showed a high incidence of premature rupture of the membranes (32.1%), PR (7.5%) and choriamnionitis (2.5%) [4].